Upload
flavio-guzman
View
1.114
Download
1
Tags:
Embed Size (px)
DESCRIPTION
Citation preview
Clinical Pharmacokinetics
Janice E. Sullivan, M.D.
Brian Yarberry, Pharm.D.
Why Study Pharmacokinetics (PK) and Pharmacodynamics (PD)?
• Individualize patient drug therapy
• Monitor medications with a narrow therapeutic index
• Decrease the risk of adverse effects while maximizing pharmacologic response of medications
• Evaluate PK/PD as a diagnostic tool for underlying disease states
Clinical Pharmacokinetics
• The science of the rate of movement of drugs within biological systems, as affected by the absorption, distribution, metabolism, and elimination of medications
Absorption• Must be able to get medications into the
patient’s body
• Drug characteristics that affect absorption:– Molecular weight, ionization, solubility, &
formulation
• Factors affecting drug absorption related to patients:– Route of administration, gastric pH, contents of GI
tract
Absorption in the Pediatric Patient
• Gastrointestinal pH changes
• Gastric emptying
• Gastric enzymes
• Bile acids & biliary function
• Gastrointestinal flora
• Formula/food interaction
Time to Peak Concentration
0102030405060708090
100
0 5 10 20 30 60 120 180
minutes
con
cen
trat
ion
IVOralRectal
Distribution• Membrane permeability
– cross membranes to site of action
• Plasma protein binding– bound drugs do not cross membranes– malnutrition = albumin = free drug
• Lipophilicity of drug– lipophilic drugs accumulate in adipose tissue
• Volume of distribution
Pediatric Distribution
• Body Composition total body water & extracellular fluid adipose tissue & skeletal muscle
• Protein Binding– albumin, bilirubin, 1-acid glycoprotein
• Tissue Binding– compositional changes
Metabolism
• Drugs and toxins are seen as foreign to patients bodies
• Drugs can undergo metabolism in the lungs, blood, and liver
• Body works to convert drugs to less active forms and increase water solubility to enhance elimination
Metabolism
• Liver - primary route of drug metabolism
• Liver may be used to convert pro-drugs (inactive) to an active state
• Types of reactions– Phase I (Cytochrome P450 system)– Phase II
Phase I reactions• Cytochrome P450 system
• Located within the endoplasmic reticulum of hepatocytes
• Through electron transport chain, a drug bound to the CYP450 system undergoes oxidation or reduction
• Enzyme induction
• Drug interactions
Phase I reactions types
• Hydrolysis
• Oxidation
• Reduction
• Demethylation
• Methylation
• Alcohol dehydrogenase metabolism
Phase II reactions
• Polar group is conjugated to the drug
• Results in increased polarity of the drug
• Types of reactions– Glycine conjugation– Glucuronide conjugation– Sulfate conjugation
Elimination
• Pulmonary = expired in the air
• Bile = excreted in feces– enterohepatic circulation
• Renal – glomerular filtration– tubular reabsorption– tubular secretion
Pediatric Elimination
• Glomerular filtration matures in relation to age, adult values reached by 3 yrs of age
• Neonate = decreased renal blood flow, glomerular filtration, & tubular function yields prolonged elimination of medications
• Aminoglycosides, cephalosporins, penicillins = longer dosing interval
Pharmacokinetic Principles
• Steady State: the amount of drug administered is equal to the amount of drug eliminated within one dosing interval resulting in a plateau or constant serum drug level
• Drugs with short half-life reach steady state rapidly; drugs with long half-life take days to weeks to reach steady state
Steady State Pharmacokinetics
• Half-life = time required for serum plasma concentrations to decrease by one-half (50%)
• 4-5 half-lives to reach steady state0
102030405060708090
100
% steady state
1 2 3 4 5
Half-life
Loading Doses
• Loading doses allow rapid achievement of therapeutic serum levels
• Same loading dose used regardless of metabolism/elimination dysfunction
0
5
10
15
20
25
30
35
40
w/ bolus
w/obolus
Linear Pharmacokinetics
• Linear = rate of elimination is proportional to amount of drug present
• Dosage increases result in proportional increase in plasma drug levels
0
20
40
60
80
100
120
dose
conc
entr
atio
n
Nonlinear Pharmacokinetics
• Nonlinear = rate of elimination is constant regardless of amount of drug present
• Dosage increases saturate binding sites and result in non- proportional increase/decrease in drug levels
05
101520253035404550
dose
conc
entr
atio
n
Michaelis-Menten Kinetics
• Follows linear kinetics until enzymes become saturated
• Enzymes responsible for metabolism /elimination become saturated resulting in non-proportional increase in drug levels
0
5
10
15
20
25
30
dose
conc
entr
atio
nphenytoin
Special Patient Populations
• Renal Disease: same hepatic metabolism, same/increased volume of distribution and prolonged elimination dosing interval
• Hepatic Disease: same renal elimination, same/increased volume of distribution, slower rate of enzyme metabolism dosage, dosing interval
• Cystic Fibrosis Patients: increased metabolism/ elimination, and larger volume of distribution dosage, dosage interval
Pharmacogenetics
• Science of assessing genetically determined variations in patients and the resulting affect on drug pharmacokinetics and pharmacodynamics
• Useful to identify therapeutic failures and unanticipated toxicity